Malignant gliomas are relatively uncommon but lethal cancers. Despite recent research efforts
in cancer therapy, the prognosis of patients with malignant gliomas has remained dismal. …

Malignant glioma is the most commonly occurring primary malignant brain tumor. It is
difficult to treat and is usually associated with an inexorable, rapidly fatal clinical course. …

… Vredenburgh has disclosed that he is a consultant for Roche, and is on the advisory board
and speakers' bureau for Genentech, Inc. Dr. Henry Friedman has disclosed that he is on the …

Purpose The prognosis for patients with recurrent glioblastoma multiforme is poor, with a
median survival of 3 to 6 months. We performed a phase II trial of bevacizumab, a monoclonal …

Purpose: Recurrent grade III-IV gliomas have a dismal prognosis with minimal improvements
in survival seen following currently available salvage therapy. This study was conducted to …

Purpose Immunologic targeting of tumor-specific gene mutations may allow precise
eradication of neoplastic cells without toxicity. Epidermal growth factor receptor variant III (EGFRvIII) …

Purpose To evaluate the efficacy and tolerability of gefitinib (ZD1839, Iressa; AstraZeneca,
Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients …

After stimulation, dendritic cells (DCs) mature and migrate to draining lymph nodes to induce
immune responses 1 . As such, autologous DCs generated ex vivo have been pulsed with …

There are several deficiencies in the stated aim. Firstly, there is no mention of the intended
comparison group, which we later find are actually 2 arms from previous studies and 1 arm …

Epidermal growth factor receptor variant III (EGFRvIII) is a tumor-specific mutation widely
expressed in glioblastoma multiforme (GBM) and other neoplasms, but absent from normal …